Expression of HER2 and C-KIT in Nasopharyngeal Carcinoma: Implications for a New Therapeutic Approach

Modern Pathology

Volumn 16, Issue 10, 2003, Pages 1035-1040

  Bar Sela, G ^a,b   Kuten, A ^a   Ben Eliezer, S ^a   Gov Ari, E ^a   Ben Izhak, O ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

C KIT; HER2; Nasopharyngeal carcinoma

Indexed keywords

DNA; IMATINIB; STEM CELL FACTOR;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; ETHNOLOGY; FEMALE; GENDER; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0142040159     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000089778.48167.91     Document Type: Article

References (29)

1. Parkin DW, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80: 827-41.
2. Kuten A, Cohen Y, Lavie R, et al. Update on nasopharyngeal carcinoma in northern Israel. Strahlenther Onkol 1994;170: 565-70.
3. Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal cancer treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-70.
4. Sham JS, Choy D, Choi PH. Nasopharyngeal carcinoma: the significance of neck node involvement in relation to the pattern of distant failure. Br J Radiol 1990;63:108-13.
5. Al-Sarraf M, LeBlanc M, Giri S, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16:1310-7.
6. Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000;36: 170-6.
7. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogen. Science 1987;235:177-82.
8. Gershenson DM, Tortolero-Luna G, Malpica A, et al. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gynecol Clin North Am 1996;23:475-543.
9. Allgayer H, Babic R, Gruetzner KU, et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000;18:2201-9.
10. Smit EF, Groen HJ, Splinter TA, et al. New prognostic factors in resectable non-small cell lung cancer. Thorax 1996;51: 638-46.
11. Roychowdhury DF, Tseng A Jr, Fu KK, et al. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and c-erbB2 expression. Cancer 1996;77:1419-26.
12. Yan J, Fang Y, Huang BJ, et al. Absence of evidence for HER2 amplification in nasophryngeal carcinoma. Cancer Genet Cytogenet 2002;132:116-9.
13. Shnayder Y, Kuriakose MA, Yee H, et al. Adhesion molecules as prognostic factors in nasopharyngeal carcinoma. Laryngoscope 2001;111:1842-6.
14. Yazici H, Altun M, Alatli C, et al. c-erbB-2 gene amplification in nasopharyngeal carcinoma. Cancer Invest 2000;18: 6-10.
15. Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320: 415-21.
16. Qiu F, Ray P, Brown K, et al. Primary structure of c-kit relationship with the CSF-1/PDGF receptor kinase family oncogenic terminus. EMBO J 1988;7:1003-11.
17. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998;28: 498-504.
18. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition clinical histological immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
19. Bokemeyer C, Kuczyk MA, Dunn T, et al. Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissues and malignant germ-cell tumours. J Cancer Res Clin Oncol 1996;122:301-6.
20. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
21. Demetri GD, Von-Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
22. Smithey BE, Pappo AS, Hill DA. c-kit expression in pediatric solid tumors. A comparative immunohistochemical study. Am J Surg Pathol 2002;26:486-92.
23. Makhlouf HR, Remotti HE, Ishak KG. Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol 2002;26:493-7.
24. Holst VA, Marshall CE, Moskaiuk CA, et al. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999;12:956-60.
25. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
26. Hornick JL, Fletcher CDM. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-93.
27. Sabah M, Leader M, Kay E. The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem Mol Morphol 2003;11:56-61.
28. Lonardo F, Pass HI, Lucas DR. Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol 2003;11:51-5.
29. Miettinen M. New challenges in the identification of gastrointestinal stromal tumors and other possible KIT-driven tumors. Am J Clin Pathol 2002;117:183-5.